146 related articles for article (PubMed ID: 24865335)
1. The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model.
Bezard E; Pioli EY; Li Q; Girard F; Mutel V; Keywood C; Tison F; Rascol O; Poli SM
Mov Disord; 2014 Jul; 29(8):1074-9. PubMed ID: 24865335
[TBL] [Abstract][Full Text] [Related]
2. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.
Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O
Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664
[TBL] [Abstract][Full Text] [Related]
3. Combined fenobam and amantadine treatment promotes robust antidyskinetic effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
Ko WK; Pioli E; Li Q; McGuire S; Dufour A; Sherer TB; Bezard E; Facheris MF
Mov Disord; 2014 May; 29(6):772-9. PubMed ID: 24610195
[TBL] [Abstract][Full Text] [Related]
4. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.
Morin N; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2010 Jun; 58(7):981-6. PubMed ID: 20074579
[TBL] [Abstract][Full Text] [Related]
5. AQW051, a novel and selective nicotinic acetylcholine receptor α7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys.
Di Paolo T; Grégoire L; Feuerbach D; Elbast W; Weiss M; Gomez-Mancilla B
Parkinsonism Relat Disord; 2014 Nov; 20(11):1119-23. PubMed ID: 25172125
[TBL] [Abstract][Full Text] [Related]
6. The plasmalogen precursor analog PPI-1011 reduces the development of L-DOPA-induced dyskinesias in de novo MPTP monkeys.
Bourque M; Grégoire L; Di Paolo T
Behav Brain Res; 2018 Jan; 337():183-185. PubMed ID: 28917506
[TBL] [Abstract][Full Text] [Related]
7. MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates.
Morin N; Grégoire L; Morissette M; Desrayaud S; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Mar; 66():355-64. PubMed ID: 22884464
[TBL] [Abstract][Full Text] [Related]
8. Contribution of brain serotonin subtype 1B receptors in levodopa-induced motor complications.
Morin N; Morissette M; Grégoire L; Rajput A; Rajput AH; Di Paolo T
Neuropharmacology; 2015 Dec; 99():356-68. PubMed ID: 26254863
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
10. Chronic treatment with MPEP, an mGlu5 receptor antagonist, normalizes basal ganglia glutamate neurotransmission in L-DOPA-treated parkinsonian monkeys.
Morin N; Morissette M; Grégoire L; Gomez-Mancilla B; Gasparini F; Di Paolo T
Neuropharmacology; 2013 Oct; 73():216-31. PubMed ID: 23756168
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.
Dekundy A; Gravius A; Hechenberger M; Pietraszek M; Nagel J; Tober C; van der Elst M; Mela F; Parsons CG; Danysz W
J Neural Transm (Vienna); 2011 Dec; 118(12):1703-16. PubMed ID: 21161716
[TBL] [Abstract][Full Text] [Related]
12. Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.
Jourdain VA; Morin N; Grégoire L; Morissette M; Di Paolo T
J Neurosurg; 2015 Dec; 123(6):1383-93. PubMed ID: 25932606
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.
Bezard E; Hill MP; Crossman AR; Brotchie JM; Michel A; Grimée R; Klitgaard H
Eur J Pharmacol; 2004 Feb; 485(1-3):159-64. PubMed ID: 14757136
[TBL] [Abstract][Full Text] [Related]
14. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease.
Johnston TH; Fox SH; McIldowie MJ; Piggott MJ; Brotchie JM
J Pharmacol Exp Ther; 2010 Jun; 333(3):865-73. PubMed ID: 20231306
[TBL] [Abstract][Full Text] [Related]
15. Effect of histamine H2 receptor antagonism on levodopa-induced dyskinesia in the MPTP-macaque model of Parkinson's disease.
Johnston TH; van der Meij A; Brotchie JM; Fox SH
Mov Disord; 2010 Jul; 25(10):1379-90. PubMed ID: 20310030
[TBL] [Abstract][Full Text] [Related]
16. The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.
Huot P; Johnston TH; Fox SH; Newman-Tancredi A; Brotchie JM
Neuropharmacology; 2015 Oct; 97():306-11. PubMed ID: 26071982
[TBL] [Abstract][Full Text] [Related]
17. An mGlu4-Positive Allosteric Modulator Alleviates Parkinsonism in Primates.
Charvin D; Di Paolo T; Bezard E; Gregoire L; Takano A; Duvey G; Pioli E; Halldin C; Medori R; Conquet F
Mov Disord; 2018 Oct; 33(10):1619-1631. PubMed ID: 30216534
[TBL] [Abstract][Full Text] [Related]
18. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl) pyridine decreases striatal VGlut2 expression in association with an attenuation of L-DOPA-induced dyskinesias.
Marin C; Bonastre M; Aguilar E; Jiménez A
Synapse; 2011 Oct; 65(10):1080-6. PubMed ID: 21484883
[TBL] [Abstract][Full Text] [Related]
19. Cholinergic manipulation of motor disability and L-DOPA-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmosets.
Jackson MJ; Swart T; Pearce RK; Jenner P
J Neural Transm (Vienna); 2014 Feb; 121(2):163-9. PubMed ID: 23959162
[TBL] [Abstract][Full Text] [Related]
20. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Sid-Otmane L; Hamadjida A; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Michaud V; Beaudry F; Panisset M; Huot P
Eur J Pharmacol; 2020 Apr; 873():172957. PubMed ID: 32004527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
